Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck's deal flow

Merck's deal flow

Partner Disease category Potential value Compound Milestones Upfront/ Equity R&D funding Sales

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE